Johnson & Johnson (JNJ): $35.61 million was the positive money flow into the stock on Thursday and the up/down ratio of ticks was also in favor of the bulls at 1.31. The value of trades done on upticks was $152.2 million, whereas, trades done on downticks were valued at $116.59 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $60.19 million worth stocks on upticks, which is a bullish indication. The downticks accounted only for $16.08 million worth of block trades showing a lack of interest among the large traders to sell the stock down. The up/down ratio of 3.74 was strongly in favor of the bulls. The money flow in block trades was $44.11 million. Johnson & Johnson (JNJ) fell $0.13 traded at $122.51, a change of -0.11% over the previous day. The stock is 1.01% for the week.
Johnson & Johnson (JNJ) : The consensus price target for Johnson & Johnson (JNJ) is $116.17 for the short term with a standard deviation of $9.61. The most optimist securities analyst among the 12 who monitor the stock believes that the stock can reach $125, however, the pessimist price target for the company is $93. The stock has recorded a 20-day Moving Average of 4% and the 50-Day Moving Average is 6.65%.
Johnson & Johnson (NYSE:JNJ): The stock opened at $122.59 on Thursday but the bulls could not build on the opening and the stock topped out at $122.81 for the day. The stock traded down to $122.01 during the day, due to lack of any buying support eventually closed down at $122.51 with a loss of -0.11% for the day. The stock had closed at $122.64 on the previous day. The total traded volume was 6,058,727 shares.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.